Commentary|Articles|August 14, 2026

FAQ: When and How to Discontinue Lenalidomide Maintenance in Multiple Myeloma

Fact checked by: Sabrina Serani

Sagar Lonial, MD, provides commentary on the key questions raised by recent data on lenalidomide maintenance for patients with newly-diagnosed multiple myeloma.

For years, questions have lingered about the tradeoff of delaying disease progression vs additional toxicity with prolonged maintenance therapy in multiple myeloma, but it has been difficult to confirm whether patients could discontinue maintenance, and when it was safest to do so.